Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 16, 2024

SELL
$3.17 - $6.17 $640 - $1,246
-202 Closed
0 $0
Q1 2022

Aug 16, 2024

BUY
$4.16 - $13.72 $840 - $2,771
202 New
202 $1.09 Million
Q1 2021

Aug 16, 2024

SELL
$16.56 - $25.46 $132 - $203
-8 Closed
0 $0
Q3 2020

Aug 16, 2024

SELL
$16.59 - $24.79 $331 - $495
-20 Reduced 71.43%
8 $133,000
Q2 2020

Aug 16, 2024

SELL
$16.86 - $23.44 $741 - $1,031
-44 Reduced 61.11%
28 $648,000
Q1 2020

Aug 16, 2024

SELL
$14.47 - $27.96 $3,024 - $5,843
-209 Reduced 74.38%
72 $1.29 Million
Q4 2019

Aug 16, 2024

BUY
$15.87 - $23.12 $4,459 - $6,496
281 New
281 $6.07 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $236M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Td Private Client Wealth LLC Portfolio

Follow Td Private Client Wealth LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Private Client Wealth LLC, based on Form 13F filings with the SEC.

News

Stay updated on Td Private Client Wealth LLC with notifications on news.